Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. (Record no. 21847856)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01869 a2200529 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250516094850.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201212s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1538-8514 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1158/1535-7163.MCT-11-0997 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Burris, Howard A |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20121217 |
| 245 00 - TITLE STATEMENT | |
| Title | Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Molecular cancer therapeutics |
| Date of publication, distribution, etc. | Aug 2012 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1820-8 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carboplatin |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Indazoles |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Maximum Tolerated Dose |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasm Staging |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Paclitaxel |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pyrimidines |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sulfonamides |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dowlati, Afshin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Moss, Rebecca A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Infante, Jeffrey R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Jones, Suzanne F |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Spigel, David R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Levinson, Kelly T |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lindquist, Diana |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gainer, Shelby D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dar, Mohammed M |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Suttle, A Benjamin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ball, Howard A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tan, Antoinette R |
| 773 0# - HOST ITEM ENTRY | |
| Title | Molecular cancer therapeutics |
| Related parts | vol. 11 |
| -- | no. 8 |
| -- | p. 1820-8 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1158/1535-7163.MCT-11-0997">https://doi.org/10.1158/1535-7163.MCT-11-0997</a> |
| Public note | Available from publisher's website |
No items available.